Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. News
  7. Summary
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celyad Oncology Doses First Patient in Trial of Colorectal Cancer Treatment

12/16/2021 | 04:28am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
CELYAD ONCOLOGY SA 4.61% 1.95 Real-time Quote.-46.97%
MERCK & CO., INC. -2.07% 91.82 Delayed Quote.22.33%
All news about CELYAD ONCOLOGY SA
05/17Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
AQ
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05CELYAD ONCOLOGY SA : 1st quarter results
CO
05/05CELYAD ONCOLOGY SA : Proxy Statments
CO
04/01CELYAD ONCOLOGY SA : Ordinary general shareholder meeting
CO
03/25TRANSCRIPT : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022
CI
03/25CELYAD ONCOLOGY : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
PU
03/25CELYAD ONCOLOGY : Letter to Shareholders – March 2022
PU
03/24Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/24Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
AQ
More news
Analyst Recommendations on CELYAD ONCOLOGY SA
More recommendations
Financials
Sales 2022 7,27 M 7,76 M 7,76 M
Net income 2022 -34,7 M -37,1 M -37,1 M
Net cash 2022 9,67 M 10,3 M 10,3 M
P/E ratio 2022 -1,38x
Yield 2022 -
Capitalization 42,1 M 45,2 M 45,0 M
EV / Sales 2022 4,46x
Capi. / Sales 2023 4,77x
Nbr of Employees 98
Free-Float 60,2%
Chart CELYAD ONCOLOGY SA
Duration : Period :
Celyad Oncology SA Technical Analysis Chart | CYAD | BE0974260896 | MarketScreener
Technical analysis trends CELYAD ONCOLOGY SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,86 €
Average target price 11,00 €
Spread / Average Target 490%
EPS Revisions
Managers and Directors
Filippo Joseph Petti Director, Chief Executive & Financial Officer
Michel E. Lussier Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Peggy Sotiropoulou Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CELYAD ONCOLOGY SA-46.97%45
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232